What is the appropriate dosing regimen of apixaban (Eliquis) for a femoral deep‑vein thrombosis?

Apixaban Dosing for Femoral DVT

For acute femoral deep vein thrombosis, initiate apixaban at 10 mg orally twice daily for the first 7 days, then reduce to 5 mg orally twice daily for at least 3 months. 1

Initial Treatment Phase (First 7 Days)

• Apixaban 10 mg PO twice daily for 7 days
• No parenteral anticoagulation (heparin bridging) is required—apixaban can be started immediately upon diagnosis 2
• This distinguishes apixaban from dabigatran and edoxaban, which require 5-10 days of parenteral anticoagulation first 3, 2

Continuation Phase (Day 8 through Month 3-6)

• Apixaban 5 mg PO twice daily after completing the initial 7-day course 1
• Continue for a minimum of 3 months 3, 4
• The 2016 CHEST guidelines and 2021 ACC consensus support this regimen, which demonstrated noninferiority to enoxaparin/warfarin with significantly less bleeding (0.6% vs 1.8% major bleeding, P<0.001) 5

Extended/Secondary Prevention Phase (After 6 Months)

After completing at least 6 months of treatment, consider extended anticoagulation based on VTE provocation status:

For Unprovoked DVT or Persistent Risk Factors:

• Apixaban 2.5 mg PO twice daily is recommended for extended therapy 2, 6, 4, 1
• This reduced dose provides effective VTE prevention with lower bleeding risk compared to full-dose anticoagulation 6, 4
• The 2021 CHEST guidelines suggest reduced-dose apixaban over full-dose for extended therapy 4

For Provoked DVT (Transient Risk Factor):

• Discontinue anticoagulation after 3 months if the provoking factor was major and transient (e.g., surgery) 4
• Consider extended therapy if minor transient risk factor or additional enduring risk factors present 7

Special Populations

Cancer-Associated DVT:

• Same dosing regimen: 10 mg twice daily × 7 days, then 5 mg twice daily 8, 9
• LMWH remains preferred by some guidelines, but apixaban is an acceptable alternative, particularly for patients without gastric/gastroesophageal lesions 3, 8, 9
• The CARAVAGGIO trial demonstrated apixaban was noninferior to dalteparin (5.6% vs 7.9% recurrent VTE) with similar bleeding rates 10
• For extended therapy in cancer patients after 6 months, reduced-dose apixaban 2.5 mg twice daily is noninferior to 5 mg twice daily with less bleeding 11

Renal Impairment:

• CrCl 15-29 mL/min: Use with caution; consider dose reduction or alternative anticoagulant 1
• CrCl <15 mL/min: Avoid apixaban; use UFH or warfarin instead 3, 1

Drug Interactions:

• Combined P-gp and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir): Reduce dose by 50% 1
• If already on 2.5 mg twice daily, avoid these combinations 1

Key Advantages of Apixaban for DVT

• No parenteral lead-in required (unlike dabigatran/edoxaban) 3, 2
• No routine monitoring needed (unlike warfarin)
• Lower bleeding risk than warfarin/enoxaparin regimens 5
• Twice-daily dosing may improve adherence compared to once-daily agents in some patients
• Reduced-dose option available for extended therapy 6, 4

Common Pitfalls to Avoid

1. Don't use parenteral anticoagulation first—apixaban is started directly, unlike dabigatran/edoxaban
2. Don't forget the 7-day loading phase—10 mg twice daily is critical for initial treatment
3. Don't continue 10 mg twice daily beyond 7 days—this increases bleeding risk without added benefit
4. Don't use 2.5 mg twice daily for acute treatment—this dose is only for extended prophylaxis after ≥6 months of therapeutic anticoagulation
5. Reassess duration at 3 months—determine if extended therapy is warranted based on provocation status and bleeding risk 4